Center for Devices and Radiological Health

Center for Devices and Radiological Health. It is a branch of the Food and Drug Administration within the United States Department of Health and Human Services, responsible for ensuring the safety and effectiveness of medical devices and eliminating unnecessary radiation exposure from electronic products. The center regulates a vast array of products, from simple tongue depressors to complex pacemaker systems and computed tomography scanners. Its work impacts public health by overseeing the lifecycle of medical technology, from pre-market review through post-market surveillance.

History and mission

The center was formally established in 1971 through the merger of the Bureau of Radiological Health and the Bureau of Medical Devices, consolidating federal oversight of these product categories. Its creation was influenced by growing public and congressional concern over device safety, exemplified by issues with the Dalkon Shield intrauterine device, which later culminated in the passage of the Medical Device Amendments of 1976. This critical legislation, signed by President Gerald Ford, granted the Food and Drug Administration explicit authority to classify and regulate medical devices based on risk. The core mission of the center is to protect and promote public health by ensuring patients and providers have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products.

Organizational structure

The center is headquartered in White Oak, Maryland, and is led by a director who reports to the Commissioner of Food and Drugs. Its operations are divided into several key offices, including the Office of Product Evaluation and Quality, which manages pre-market reviews and compliance, and the Office of Regulatory Programs. Other significant components include the Office of Health Technology for strategic direction and the Office of the Center Director. The center works closely with other FDA components, such as the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, particularly on combination products like drug-eluting stents. It also engages with international regulatory bodies through initiatives like the International Medical Device Regulators Forum.

Regulatory responsibilities

The center oversees the entire lifecycle of medical devices in the United States, utilizing a risk-based classification system (Class I, II, or III) established by the Medical Device Amendments of 1976. For pre-market approval, most Class I and some Class II devices can enter the market via 510(k) clearance, while higher-risk Class III and some Class II devices typically require a more rigorous Premarket Approval application. The center also regulates radiation-emitting electronic products under the Radiation Control for Health and Safety Act of 1968, covering items like microwave ovens, cell phones, and laser products. Its post-market authorities include monitoring adverse event reports, conducting inspections of manufacturing facilities, and ordering recalls, such as those for certain metal-on-metal hip implants.

Key programs and initiatives

A major ongoing initiative is the implementation of the 21st Century Cures Act, which promotes innovation and streamlined review pathways for breakthrough devices. The center runs the Breakthrough Devices Program, designed to expedite the development and assessment of devices that treat life-threatening conditions. Other significant programs include the Sentinel Initiative, a post-market surveillance system that leverages large-scale electronic health data from partners like the Centers for Medicare & Medicaid Services. The center also leads the MDUFA program, a user fee agreement with industry that provides funding for device review activities, and maintains the FDA's Unique Device Identification system to improve device traceability.

Impact and controversies

The center's work has profoundly shaped the medical device landscape, facilitating access to innovations like artificial heart valves and continuous glucose monitors. However, its regulatory processes have been the subject of significant debate and scrutiny. Critics, including members of the United States Congress and the Institute of Medicine, have questioned the 510(k) clearance pathway, arguing it sometimes allows devices to market without sufficient clinical data, citing cases like problematic surgical mesh. High-profile device recalls, such as those involving Essure birth control implants, have spurred congressional hearings and calls for reform. The center continually adapts its policies in response to such challenges, balancing the goals of safety, innovation, and patient access under the oversight of the Department of Health and Human Services. Category:Food and Drug Administration Category:Medical and health organizations based in the United States Category:Government agencies established in 1971